Cellectricon strengthens Scientific Advisory Board through appointment of Professor Camilla Svensson
To further enhance Cellectricon’s expertise in Chronic Pain drug discovery, the company is today announcing the addition of another highly respected specialist, Professor Camilla Svensson, to its scientific advisory board.
Professor Svensson obtained her PhD at UC San Diego, where she also held a postdoctoral research position at the Department of Medicine. She subsequently moved on to Karolinska Institute, Stockholm, Sweden, where she today holds a position as Associate Professor and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology. Her research is focused on investigating the role of neuroinflammation in the peripheral and central nervous system, with particular focus on pain mechanisms in conditions with joint inflammation and autoimmunity, such as rheumatoid arthritis.
“We are very pleased to welcome Camilla to our Scientific Advisory Board, where she will bring extensive disease area knowledge which nicely complements the skill sets of our other board members” said Cellectricon’s CSO, Dr Paul Karila. “Professor Svensson will be a key contributor in shaping our chronic pain R&D strategy, and she will also provide valuable scientific support to our ongoing projects.”
The partnership promises to further advance Cellectricon’s Discovery Services, giving clients access to ever more disease-relevant outcomes.
For more information on Cellectricon’s Pain and CNS Discovery Services, please visit the Discovery Services Page.